Clinical Trials Logo

Opioid-Related Disorders clinical trials

View clinical trials related to Opioid-Related Disorders.

Filter by:

NCT ID: NCT00135759 Completed - Clinical trials for Substance-Related Disorders

Addition of Naltrexone to Methadone Taper

Start date: April 2005
Phase: Phase 2
Study type: Interventional

There is a continuing search for more effective opiate detoxification treatments. This study's purpose is to investigate the effects of adding very low doses of naltrexone to a methadone tapering treatment in opioid dependent individuals.

NCT ID: NCT00134914 Completed - Clinical trials for Opioid-Related Disorders

Effects of Buprenorphine/Naloxone Administered in Different Ways For Treating Opioid Dependence

Start date: August 1996
Phase: N/A
Study type: Interventional

Buprenorphine is a treatment for opioid dependence. Naloxone is given in addition to buprenorphine in order to limit the abuse potential that is commonly associated with buprenorphine. The purpose of this study is to examine the effects of buprenorphine/naloxone when given through different routes and at different doses.

NCT ID: NCT00134888 Completed - Clinical trials for Opioid-Related Disorders

Blockade Efficacy of Buprenorphine/Naloxone For Opioid Dependence

Start date: December 2000
Phase: N/A
Study type: Interventional

Buprenorphine, a treatment for opioid dependence, can be mixed with naloxone, to limit abuse potential. The purpose of this study is to examine the effectiveness of buprenorphine/naloxone that is given at less than daily intervals, in order to prevent withdrawal symptoms associated with stopping opioid abuse.

NCT ID: NCT00134875 Terminated - Clinical trials for Opioid-Related Disorders

Assessing Abuse Potential of Parenteral Buprenorphine/Naloxone in Non-Dependent Opioid Abusers

Start date: December 2000
Phase: N/A
Study type: Interventional

Buprenorphine, a treatment for opioid dependence, can be mixed with another drug, naloxone, to limit abuse potential. Parenteral administration (intravenous or intramuscular injection) of buprenorphine/naloxone causes withdrawal symptoms in opioid dependent individuals. However, naloxone does not cause withdrawal symptoms in non-dependent opioid abusers. This study will investigate whether naloxone decreases the opioid agonist effect from injected buprenorphine, hence decreasing the abuse potential of buprenorphine/naloxone, in non-dependent opioid abusers.

NCT ID: NCT00130819 Completed - HIV Infections Clinical Trials

Comparison of HIV Clinic-based Treatment With Buprenorphine Versus Referred Care in Heroin-dependent Participants

Start date: November 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the effectiveness of two approaches to treating HIV-infected patients who are addicted to opioid drugs (e.g., heroin) in an inner-city HIV clinic. The two approaches are: - Case management and referral - participants are managed by a case manager and referred to a specialized drug treatment center where they receive counseling and medications for opioid-dependence (e.g., methadone or buprenorphine); or - Clinic-based treatment - participants receive counseling and treatment with buprenorphine at the HIV clinic.

NCT ID: NCT00129298 Completed - Clinical trials for Cocaine-Related Disorders

Effectiveness of Tiagabine for Cocaine Dependence in Methadone-Maintained Individuals - 1

Start date: December 2004
Phase: Phase 2
Study type: Interventional

Many opioid-dependent individuals are also dependent on cocaine. Methadone is a widely used and effective method for treating opioid dependence. However, it is not effective in treating other drugs of abuse. The purpose of this study is to determine the effectiveness of another drug, tiagabine, for treating cocaine dependence in opioid-dependent individuals already receiving methadone treatment.

NCT ID: NCT00125515 Completed - Opioid Dependence Clinical Trials

Memantine and Naltrexone Treatment for Opioid Dependence

NAMHS-1
Start date: June 2005
Phase: Phase 2
Study type: Interventional

The goal of this study is to test the efficacy of memantine (a noncompetitive NMDA receptor antagonist) as an adjunct to the maintenance treatment with naltrexone in detoxified heroin-dependent individuals.

NCT ID: NCT00124358 Recruiting - HIV Infections Clinical Trials

Buprenorphine and Integrated HIV Care Evaluation

Start date: August 2005
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess the feasibility, cost and effectiveness of interventions designed to integrate buprenorphine treatment for opioid dependence into HIV primary care in ten HIV care centers in the U.S.

NCT ID: NCT00078130 Completed - Clinical trials for Opioid-Related Disorders

Buprenorphine/Naloxone - Facilitated Rehabilitation for Opioid Dependent Adolescents - 1

Start date: July 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare two 3-month treatments for adolescents/young adults who are addicted to heroin: buprenorphine/naloxone combined with psychosocial therapy and treatment as usual, a 7-14 day detoxification with buprenorphine and three weeks of psychosocial therapy.

NCT ID: NCT00078117 Completed - Clinical trials for Opioid-Related Disorders

Suboxone: (Buprenorphine/Naloxone) Comparison of Two Taper Schedules - 1

Start date: June 2003
Phase: Phase 3
Study type: Interventional

The purpose of this protocol is to to compare the clinical utility of two dosage tapering regimens in Buprenorphine/Naloxone stabilized subjects for opiate detoxification.